Skip to main content
SpringerLink
Log in

Empfehlung für Mädchen und Jungen

HPV-Impfung: Ab dem 9. Lebensjahr bei jedem Praxisbesuch ansprechen!

  • Gynäkoonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Robert Koch-Institut. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. Epid Bull. 2018;26:233-51

  2. Gemeinsamer Bundesausschuss. Schutzimpfungs-Richtlinie (SI-RL): Umsetzung der STIKO-Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. 2018;Verfügbar unter https://www.g-ba.de/beschluesse/3502/ Letzter Zugriff am 14. Juni 2019

  3. Gross G et al. S3-Leitlinie zur ImpfpräventionHPV-assoziierter Neoplasien. AWMF-Register Nr.082/002 2013; verfügbar unter www.awmf.org/leitlinien/detail/ll/082-002.html Letzter Zugriff am 17. Juni 2019

  4. Loenenbach AD et al. Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany - Results from a nationwide population-based survey. Int J Infect Dis. 2019;83:3-11

  5. Han JJ et al. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncol. 2017;3(6):810-6

  6. McDonald SA et al. Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control.2017;28(3):203-14

  7. Donken R et al. High effectiveness of the bivalent HPV vaccine up to six years post-vaccination against incident and persistent HPV infections in young Dutch females. J Infect Dis. 2018;217(10):1579-89

  8. Huh WK et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017;390(10108):2143-59

  9. Van Damme P et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205-12

  10. Patel C et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23(41)

  11. Gilca V et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018;36(46):7017-24

  12. Verdoodt F et al. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: A Danish nationwide cohort study. Clin Infect Dis. 2020;70(4):608-14

Download references

Author information

Authors and Affiliations

  1. Klinikum Innenstadt d. LMU München\/Sekt. Klin. Infektiologie, Pettenkoferstraße 8 a, 80336, München, Germany

    Ulrich Seybold

Authors
  1. Ulrich Seybold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Seybold.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seybold, U. HPV-Impfung: Ab dem 9. Lebensjahr bei jedem Praxisbesuch ansprechen! . Im Fokus Onkologie 23, 34–36 (2020). https://doi.org/10.1007/s15015-020-2357-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-020-2357-7

Search

Navigation